Stock Events

Stock Events

Search...

Acasti Pharma

$3.37

131

-$0.03-0.88% Friday 20:00

Statistics

Day High

3.45

Day Low

3.2

52W High

3.6

52W Low

1.98

Volume

27,682

Avg. Volume

32,280

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

17FebExpected

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

-0.54

-0.39

-0.24

-0.09

Expected EPS

-0.333333

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2018

2019

2020

2021

2022

2023

0Revenue

-12.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.

AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.

Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.

Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.

Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.

GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.

AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.

Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.

Bristol-Myers Squibb

Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

About

Health Technology

Pharmaceuticals: Other

Manufacturing

Medicinal and Botanical Manufacturing

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Show more...

CEO

Janelle D'Alvise

Employees

32

Country

CA

ISIN

CA00430K8730

Listings

0 Comments

Share your thoughts

FAQ

What is Acasti Pharma stock price today?▼

The current price of ACST is $3.37 USD — it has decreased by -0.88% in the past 24 hours. Watch Acasti Pharma stock price performance more closely on the chart.

What is Acasti Pharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Acasti Pharma stocks are traded under the ticker ACST.

What is Acasti Pharma revenue for the last year?▼

Acasti Pharma revenue for the last year amounts to 0 USD.

What is Acasti Pharma net income for the last year?▼

ACST net income for the last year is -12.85M USD.

How many employees does Acasti Pharma have?▼

As of April 01, 2026, the company has 32 employees.

In which sector is Acasti Pharma located?▼

Acasti Pharma operates in the Professional, Scientific, and Technical Services sector.

When did Acasti Pharma complete a stock split?▼

The last stock split for Acasti Pharma was on July 10, 2023 with a ratio of 1:6.

Where is Acasti Pharma headquartered?▼

Acasti Pharma is headquartered in Laval, CA.